|
BCN1147 |
3,4-O-Isopropylidene shikimic acid
|
|
1. 3,4-Oxo- isopropylidene-shikimic acid has significant anti-inflammatory effect which may be related to inhibiting the production of prostaglandin E2 and protecting free radical against oxidation.
2. 3,4-Oxo-isopropylidene-shikimic acid has protective effects on experimental colitis induced by trinitrobenzenesulfonic acid in rats, probably due to an antioxidant action.
3. 3,4-Oxo-isopropylidene-shikimic acid has anti-thrombosis effect, it inhibits thrombosis by anti-platelet-aggregation.
4. 3,4-Oxo-isopropylidene shikimic acid relieves the brain edema of rats subjected to MCAT by improving the energy metabolism and Na +, K +-ATPase activity in rat brain tissue.
5. 3,4-Oxo-isopropylidene-shikimic acid can inhibit adhesion of polymorphonuclear leukocyte to TNF-alpha-induced endothelial cells in vitro.
6. 3,4-Oxo-isopropylidene-shikimic acid has analgesic and antioxidant activities, it exhibits moderate antioxidant activity by scavenging the superoxide radical and hydroxyl radical with IC50 values of 0.214 and 0.450 ug/mL, respectively.
7. 3,4-Oxo-isopropylidene-shikimic acid has exhibited ameliorative effect on cognitive impairment in experimental animal models of dementia, it can promote adipogenesis by up-regulating expressions of C/EBP β, PPAR γ, C/EBP α, aP2 and FAS, and also stimulate adipokines during adipocyte differentiation, suggests that stimulation of adipokines and cognitive enhancing effect of 3,4-oxo-isopropylidene-shikimic acid have some relationship. |
|
BCN1178 |
Salvigenin
|
|
Salvigenin, a potent hMAO-A [monoamine oxidases (MAOs)]inhibitor,
has neuroprotective, antitumor and immunomodulatory effects, it has potential to ameliorate Streptozotocin-induced diabetes mellitus and heart complications in rats. Salvigenin has dose-dependent analgesic effect so that it can be useful in controlling of inflammations, acute and chronic pain. |
|
BCN1209 |
Eriodictyol
|
|
Eriodictyol has vasodilator, anti-inflammatory and antioxidant activities, it is an antagonist of the transient potential vanilloid 1 receptor (TRPV1) receptor.
Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance, it attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the blood-retinal barrier (BRB) in early diabetic rats. It may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis. |
|
BCN1210 |
Bulleyaconitine A
|
|
Bulleyaconitine A is an analgesic and antiinflammatory drug, it has several potential targets, including voltage-gated Na+ channels. It displays long-acting local anesthetic properties in vitro and in vivo, it has been approved for the treatment of chronic pain and rheumatoid arthritis in China, it has the suppressive effect on some immune function of Balb/c mice. |
|
BCN1212 |
Secoisolariciresinol Diglucoside
|
|
Secoisolariciresinol diglucoside(SDG) is a phytoestrogen, estrogens and phytoestrogen from soy have been reported to have mild hypotensive effects, and SDG is a long-acting hypotensive agent, and that the hypotensive effect is mediated through the guanylate cyclase enzyme. SDG has strong antioxidant activity, cardioprotective effects, reduces the blood levels of low-density lipoprotein cholesterol, and reduces the risk of hormone related cancer. |
